Filtered By:
Specialty: Endocrinology
Condition: Heart Failure
Education: Study

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 271 results found since Jan 2013.

The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes
AbstractPurpose of ReviewTo evaluate the treatment of type 2 diabetes from a cardiologist ’s view.Recent FindingsA new era in the treatment of type 2 diabetes began for the cardiologist in 2015 with the publication of the EMPA-REG outcome trial finding a significant reduction in CV death with empagliflozin (oral sodium-glucose co-transporter-2 [SGLT2] inhibitor) in patients with type 2 diabetes at increased cardiovascular risk. Shortly thereafter, the injectable glucagon-like peptide agonists (GLP-1) liraglutide and semaglutide found a significant reduction in composite major cardiovascular events (CV death, non-fatal MI...
Source: Current Diabetes Reports - November 8, 2018 Category: Endocrinology Source Type: research

Galectin ‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes
ConclusionsSerum galectin ‐3 is associated with adverse cardiovascular outcomes in persons with type 2 diabetes independent of traditional risk factors.
Source: Diabetes/Metabolism Research and Reviews - November 15, 2018 Category: Endocrinology Authors: Kathryn C.B. Tan, Ching ‐Lung Cheung, Alan C.H. Lee, Joanne K.Y. Lam, Ying Wong, Sammy W.M. Shiu Tags: RESEARCH ARTICLE Source Type: research

Resistin is a prognostic factor in type 2 diabetes.
ConclusionsHigher resistin is associated with reduced survival in T2D, irrespectively of TNF ‐α. Resistin concentration of above 11 ng/mL indicates T2D patients at an increased risk of unfavorable outcomes. Leptin was not a prognostic factor. These results suggest that in T2D, association of resistin with unfavorable outcomes might, at least in part, result from its pro‐inflammatory pr operties.
Source: Diabetes/Metabolism Research and Reviews - November 16, 2018 Category: Endocrinology Authors: Agnieszka Kap łon‐Cieślicka, Agata Tymińska, Marek Rosiak, Krzysztof Ozierański, Michał Peller, Ceren Eyileten, Agnieszka Kondracka, Justyna Pordzik, Dagmara Mirowska‐Guzel, Grzegorz Opolski, Marek Postuła, Krzysztof J. Filipiak Tags: RESEARCH ARTICLE Source Type: research

The morphofunctional features of platelets against the background of metabolic syndrome in patients with generalized marginal periodontitis
Conclusion: The presented data provide strong evidence for changes in the morphofunctional state of peripheral blood platelets in patients with generalized marginal periodontitis of mild and moderate degree against the background of metabolic syndrome.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - December 7, 2018 Category: Endocrinology Source Type: research

Association of metabolic syndrome and chronic kidney disease with atrial fibrillation: A nationwide population-based study in Korea
Atrial fibrillation (AF) is the most common cardiac arrhythmia observed in clinical practice, and its incidence and prevalence have been progressively increasing with a rise in the aging population and lifestyle changes [1,2]. AF not only affects a patient ’s quality of life due to distressing symptoms but also leads to serious long-term consequences such as stroke and heart failure [3]. The pathophysiology underlying the onset and progression of AF is a complex process that remains unclear despite thorough investigation over the past 3 decades.
Source: Diabetes Research and Clinical Practice - December 19, 2018 Category: Endocrinology Authors: Won-Seok Choe, Eue-Keun Choi, Kyung-Do Han, Eui-Jae Lee, So-Ryoung Lee, Myung-Jin Cha, Seil Oh Source Type: research

Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk.
CONCLUSION: Risk of cardiovascular disease was found increased in untreated hyperthyroid patients, and duration of decreased TSH associated with increasing risk of cardiovascular outcomes in both treated and untreated hyperthyroid individuals. This suggests that increased cardiovascular risk is not only driven by lack of treatment but also by insufficient therapy. Our results support timely treatment and careful monitoring of hyperthyroid patients in order to reduce cardiovascular risk. PMID: 30648498 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - January 18, 2019 Category: Endocrinology Tags: Thyroid Source Type: research

Incidence rate of diabetes mellitus (type II) and its related risk factors: A 10-year longitudinal study of Yazd Healthy Heart Cohort (YHHC), Iran
ConclusionIn the present study, Age, family history of DM, abdominal obesity, high triglycerides and high uric acid are the most important risk factors for diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - February 6, 2019 Category: Endocrinology Source Type: research

The incidence rate of diabetes mellitus (type II) and its related risk factors: A 10-year longitudinal study of Yazd Healthy Heart Cohort (YHHC), Iran
ConclusionIn the present study, Age, family history of DM, abdominal obesity, high triglycerides, and high uric acid are the most important risk factors for diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - February 27, 2019 Category: Endocrinology Source Type: research

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
Publication date: Available online 28 February 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Onyebuchi E Okosieme, Peter N Taylor, Carol Evans, Dan Thayer, Aaron Chai, Ishrat Khan, Mohd S Draman, Brian Tennant, John Geen, Adrian Sayers, Robert French, John H Lazarus, Lakdasa D Premawardhana, Colin M DayanSummaryBackgroundGraves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain. We evaluated cardiovascular morbidity and mortality according to the method and effectiveness of primary therapy in Graves'...
Source: The Lancet Diabetes and Endocrinology - March 1, 2019 Category: Endocrinology Source Type: research

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
ConclusionThe prevalence of CVD in patients with type 2 diabetes in clinical practice in Sweden was 28.3% during the study period, and it was 11.5% in the patients starting empagliflozin treatment. Patients of the latter cohort were, however, younger, more obese, and more likely to have unsatisfactory glycemic control, requiring additional treatment. Overall, a large proportion of type 2 diabetes patients should be considered at high cardiovascular risk.FundingBoehringer Ingelheim AB, Sweden.
Source: Diabetes Therapy - May 13, 2019 Category: Endocrinology Source Type: research

Vitamin D status and cardiovascular outcome
AbstractIntroductionVitamin D is classically involved in maintaining bone and mineral health, but it has been shown to exert many extraskeletal functions, including pleiotropic effects on cardiovascular system.Materials and methodThis review aims to summarize evidences in literature about vitamin D and cardiovascular outcome.Results and conclusionsCalcitriol or 1,25(OH)2D, the active hormone, binds to the specific nuclear receptor VDR, which is expressed in rat and human heart and vasculature and has effects on myocardiocytes, smooth cells, and endothelial cells. 25-Hydroxy-vitamin D (25OHD) represents the biomarker of vit...
Source: Journal of Endocrinological Investigation - June 5, 2019 Category: Endocrinology Source Type: research

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
ConclusionApproximately one-third of patients with T2DM in the UK have concomitant CVD.FundingMerck Sharp& Dohme Corp., a subsidiary Merck& Co., Inc., Kenilworth, NJ, USA.
Source: Diabetes Therapy - October 3, 2019 Category: Endocrinology Source Type: research

The Cardiovascular Effects of SGLT2 Inhibitors
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractIndividuals with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in individuals with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other ...
Source: Canadian Journal of Diabetes - November 29, 2019 Category: Endocrinology Source Type: research

Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractAdults with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in adults with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other phase 3 cl...
Source: Canadian Journal of Diabetes - December 13, 2019 Category: Endocrinology Source Type: research

Association of prediabetes with CKD progression and adverse cardiovascular outcomes: an analysis of the CRIC study.
CONCLUSIONS: In individuals with CKD, prediabetes was not associated with composite renal outcome, but was associated with an increased risk of proteinuria progression and adverse CV outcomes. PMID: 31943096 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - January 15, 2020 Category: Endocrinology Authors: Neves JS, Correa S, Baeta Baptista R, Bigotte Vieira M, Waikar SS, Mc Causland FR Tags: J Clin Endocrinol Metab Source Type: research